JLM based Entera Bio sets terms for $60m Nasdaq IPO
DNA Biomedical Solutions Ltd. (TASE: DNA) subsidiary Entera Bio has set the terms for a Nasdaq IPO to raise $50 million – $60 million at a company valuation
Oramed Pharma’s CEO Issues Letter to Shareholders
Jan 19, 2017 Dear Shareholders, All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment
OrCam Launched Next Generation of Artificial Vision for the Visually Impaired
Janaury 7, 2017 OrCam displayed their artificial vision technology, OrCam MyEye 2.0, at CES 2018. MyEye was been named a CES Innovation Awards honoree and a finalist in the last gadget standing
JLM based Salignostics Ltd is carrying out free saliva based pregnancy tests for a limited period of time
Dec 14, 2017 JLM based Salignostics Ltd has developed a novel pregnancy rapid home- test utilizing saliva. This is the first saliva pregnancy OTC product
Kitov Pharmaceuticals Announces Receipt of FDA’s Favorable Response to NT219’s pre-IND Meeting Package
Nov 11, 2017 – NT219 works by overcoming drug resistance of pancreatic cancer to various oncology drugs. Kitov Pharmaceuticals (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical
Granalix BioTechnologies, founded by Prof Ruth Gabizon, is marketing a Novel Food Additive Based On Pomegranate Oil For Protection From Neurodegenerative Diseases
Granalix BioTechnologies, following its commercial launch last year of GranaGard™ a food supplement based on pomegranate oil that was shown to prevent neurodegeneration diseases in mouse models,
Updated Version of Oncological Drugs Rating Tool, developed by Prof. Nathan Cherny from Shaare Zedek Medical Center
Novermber 10, 2017 The new version of an international oncological drugs rating tool, developed by Prof. Nathan Cherny from Shaare Zedek, will – for the
JLM based Neteera Expands Market Reach and Senior Management
Dec 12, 2017: Neteera Technologies Ltd. [http://www.neteera.com ] announced the addition of Jason Rudd and Ilya Vatsel to the company’s senior management team bringing a wealth
Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round
JERUSALEM, Dec. 11, 2017 (GLOBE NEWSWIRE) — BioCancell Therapeutics (TASE:BICL), http://www.biocancell.com/ a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer,
